RECRUITING

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Conditions

Pneumococcal Vaccine Esophageal Cancer Lymphopenia Chemoradiation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To learn how radiation treatment may affect your responses to vaccines against pneumonia.

Official Title

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Quick Facts

Study Start:2024-02-05

Study Completion:2025-09-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06181656

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Group 1A 2. Group 1B 3. Group 2A 4. Group 2B 5. Group 3 6. All Groups 1. Participants of all genders, races and nationalities will be solicited. 2. Age \>18 years 3. Ability to understand and the willingness to sign a written informed consent document.	* Participants with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy * Participants receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment. * Participants with psychiatric illness/social situations that would limit compliance with study requirements. * Participants with previous pneumococcal vaccination * Participants with severe allergy to any of the vaccine components

Inclusion Criteria

Exclusion Criteria

1. Group 1A
2. Group 1B
3. Group 2A
4. Group 2B
5. Group 3
6. All Groups
1. Participants of all genders, races and nationalities will be solicited.
2. Age \>18 years
3. Ability to understand and the willingness to sign a written informed consent document.

* Participants with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., Human immunodeficiency virus (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy
* Participants receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment.
* Participants with psychiatric illness/social situations that would limit compliance with study requirements.
* Participants with previous pneumococcal vaccination
* Participants with severe allergy to any of the vaccine components

Contacts and Locations

Study Contact

Steven H Lin, MD

CONTACT

(713) 563-8490

shlin@mdanderson.org

Principal Investigator

Steven H Lin, MD

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

MD Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Steven H Lin, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-05

Study Completion Date2025-09-30

Study Record Updates

Study Start Date2024-02-05

Study Completion Date2025-09-30

Terms related to this study

Additional Relevant MeSH Terms

Pneumococcal Vaccine
Esophageal Cancer
Lymphopenia
Chemoradiation